LLY
Eli Lilly and Company
—
1098.13 $
-13.8700 (%-1.25)
Previous Close: 1112
Day Low₺1088.655
Day High₺1122.33
LLY: Eli Lilly and Company Financials
LLY Income Statement
Total revenue
Net income
Gross margin TTM
83.79%
Operating margin TTM
45.56%
Net profit margin TTM
31.66%
Return on investment TTM
—
| Period end | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 65,179,000,000 | 45,042,700,000 | 34,124,100,000 | 28,541,400,000 |
| Operating income | 29,696,000,000 | 17,501,700,000 | 10,787,300,000 | 8,653,300,000 |
| Net income | 20,638,300,000 | 10,590,000,000 | 5,240,400,000 | 6,244,800,000 |
All line items
| Line item | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 65,179,000,000 | 45,042,700,000 | 34,124,100,000 | 28,541,400,000 |
| Cost of revenue | 10,564,000,000 | 8,418,300,000 | 7,082,200,000 | 6,629,800,000 |
| Gross profit | 54,615,000,000 | 36,624,400,000 | 27,041,900,000 | 21,911,600,000 |
| Research and development expenses | 13,337,500,000 | 10,990,600,000 | 9,313,400,000 | 7,190,800,000 |
| General and administrative expenses | 11,094,000,000 | 8,132,100,000 | 6,941,200,000 | 6,067,500,000 |
| Selling and marketing expenses | 0 | 0 | 0 | 0 |
| Selling, general and administrative expenses | 11,094,000,000 | 8,132,100,000 | 6,941,200,000 | 6,067,500,000 |
| Other expenses | 487,500,000 | 0 | 0 | 0 |
| Operating expenses | 24,919,000,000 | 19,122,700,000 | 16,254,600,000 | 13,258,300,000 |
| Cost and expenses | 35,483,000,000 | 27,541,000,000 | 23,336,800,000 | 19,888,100,000 |
| Net interest income | -642,000,000 | -605,400,000 | -312,300,000 | -268,800,000 |
| Interest income | 153,300,000 | 175,200,000 | 173,600,000 | 62,800,000 |
| Interest expense | 795,300,000 | 780,600,000 | 485,900,000 | 331,600,000 |
| Depreciation and amortization | 1,563,500,000 | 1,766,600,000 | 1,527,300,000 | 1,522,500,000 |
| EBITDA | 27,936,500,000 | 15,227,600,000 | 8,567,800,000 | 8,660,500,000 |
| EBIT | 26,373,000,000 | 13,461,000,000 | 7,040,500,000 | 7,138,000,000 |
| Non-operating income (excl. interest) | 3,323,000,000 | 4,040,700,000 | 3,746,800,000 | 1,515,300,000 |
| Operating income | 29,696,000,000 | 17,501,700,000 | 10,787,300,000 | 8,653,300,000 |
| Total other income/expenses (net) | -3,965,000,000 | -4,821,300,000 | -4,232,700,000 | -1,846,900,000 |
| Income before tax | 25,729,900,000 | 12,680,400,000 | 6,554,600,000 | 6,806,400,000 |
| Income tax expense | 5,091,600,000 | 2,090,400,000 | 1,314,200,000 | 561,600,000 |
| Net income from continuing operations | 20,638,300,000 | 10,590,000,000 | 5,240,400,000 | 6,244,800,000 |
| Net income from discontinued operations | 0 | 0 | 0 | 0 |
| Other adjustments to net income | 0 | 0 | 0 | 0 |
| Net income | 20,638,300,000 | 10,590,000,000 | 5,240,400,000 | 6,244,800,000 |
| Net income deductions | 0 | 0 | 0 | 0 |
| Bottom line net income | 20,638,300,000 | 10,590,000,000 | 5,240,400,000 | 6,244,800,000 |
| EPS | 23 | 12 | 6 | 7 |
| Diluted EPS | 23 | 12 | 6 | 7 |
| Weighted average shares outstanding | 898,002,000 | 900,605,000 | 899,379,000 | 950,182,000 |
| Weighted average diluted shares outstanding | 898,002,000 | 904,059,000 | 903,284,000 | 950,182,000 |